Judd W. Moul

Q: What Schools Are Affiliated With Judd W. Moul

Judd W. Moul is affiliated with the following schools: George Washington University, University of British Columbia, Uniformed Services University of the Health Sciences, Duke University, University of Pennsylvania

Judd W. Moul's AcademicInfluence.com Rankings

Judd W. Moul

Philosophy

#5488

World Rank

#8305

Historical Rank

Logic

#2758

World Rank

#3793

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Judd W. Moul Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Judd W. Moul's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guideline for the management of clinically localized prostate cancer: 2007 update. (2007) (1186)
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. (2007) (721)
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. (2003) (495)
Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. (2003) (464)
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. (2004) (410)
Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. (1994) (407)
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. (2014) (391)
Age-specific reference ranges for serum prostate-specific antigen in black men. (1996) (380)
Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. (2005) (350)
PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. (2000) (341)
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. (2008) (338)
Prostate specific antigen only progression of prostate cancer. (2000) (334)
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. (2007) (332)
The changing face of prostate cancer. (2005) (329)
Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. (2003) (289)
p53 Regulates the Expression of the Tumor Suppressor Gene Maspin* (2000) (289)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (2006) (275)
Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. (1990) (256)
Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients (2004) (251)
Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. (2003) (250)
Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. (1995) (242)
Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. (1996) (236)
Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. (2000) (232)
Erectile function outcome reporting after clinically localized prostate cancer treatment. (2007) (227)
Prostate cancer early detection. Clinical practice guidelines in oncology. (2010) (226)
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. (2012) (219)
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. (2005) (207)
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology (2010) (207)
Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome (2005) (205)
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. (2004) (201)
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. (2000) (186)
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. (2013) (184)
Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. (1996) (184)
Flaxseed Supplementation (Not Dietary Fat Restriction) Reduces Prostate Cancer Proliferation Rates in Men Presurgery (2008) (181)
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. (1998) (178)
Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. (1995) (176)
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. (2004) (171)
Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis (1998) (170)
Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. (1996) (166)
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. (1993) (166)
Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. (2017) (160)
Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. (2004) (158)
Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. (2002) (156)
NCCN clinical practice guidelines in oncology: prostate cancer early detection. (2010) (152)
Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. (2010) (150)
A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. (2000) (147)
A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. (2011) (144)
Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. (1996) (141)
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer (2007) (139)
Diagnostic potential of serum proteomic patterns in prostate cancer. (2003) (137)
Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer. (1994) (135)
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. (2013) (135)
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. (2010) (134)
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer (2004) (134)
Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database (2009) (133)
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells (2002) (133)
The development of erectile dysfunction in men treated for prostate cancer. (2001) (132)
Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. (2001) (130)
Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. (2001) (128)
A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group (2001) (125)
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. (2012) (122)
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. (2010) (118)
PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. (2003) (117)
Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. (2000) (115)
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. (2000) (113)
Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. (1992) (112)
Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy (1999) (110)
Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes (2001) (110)
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. (2008) (109)
Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation. (2002) (107)
p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. (1995) (107)
p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. (1999) (105)
Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. (2002) (104)
Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. (2005) (103)
Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. (2002) (101)
Infrequent RAS oncogene mutations in human prostate cancer (1992) (99)
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. (2009) (99)
Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone (2012) (99)
Salvage radiation in men after prostate‐specific antigen failure and the risk of death (2011) (98)
Baseline prostate-specific antigen testing at a young age. (2012) (96)
A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. (2013) (95)
HEPSIN inhibits cell growth/invasion in prostate cancer cells. (2002) (94)
Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. (2008) (93)
Rising prostate-specific antigen after primary prostate cancer therapy (2005) (93)
Screening for prostate cancer in high risk populations. (2002) (91)
The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel (2014) (91)
Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. (1998) (90)
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens (2018) (89)
Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. (2000) (88)
Prostate cancer in men of African origin (2016) (87)
Prostate specific antigen recurrence after definitive therapy. (2007) (87)
Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. (1999) (87)
Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. (2003) (86)
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. (2007) (85)
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. (2007) (82)
Optimized prostate biopsy via a statistical atlas of cancer spatial distribution (2004) (80)
What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation (2012) (80)
Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors. (1994) (80)
Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy (1997) (79)
Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center (2012) (77)
Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. (2003) (77)
Race/Ethnicity and the Intensity of Medical Monitoring Under ‘Watchful Waiting’ for Prostate Cancer (2004) (77)
PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. (2003) (77)
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study (2009) (75)
Timely diagnosis of testicular cancer. (2007) (74)
The role of radical surgery in the management of radiation recurrent and large volume prostate cancer (1991) (73)
Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. (2003) (71)
Risk factors for perineal seeding of prostate cancer after needle biopsy. (1989) (70)
Comparison of prostate‐specific antigen recurrence‐free survival in a contemporary cohort of patients undergoing either radical retropubic or robot‐assisted laparoscopic radical prostatectomy (2008) (69)
Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. (1990) (68)
Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. (1998) (68)
Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule. (1990) (68)
The role of retroperitoneal lymphadenectomy in mature teratoma of the testis. (1997) (67)
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. (2009) (66)
Targeted Prostate Biopsy Using Statistical Image Analysis (2007) (65)
Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer. (2014) (64)
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. (2009) (64)
Pathologic stage T2a and T2b prostate cancer in the recent prostate‐specific antigen era: Implications for unilateral ablative therapy (2008) (64)
Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. (2008) (64)
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. (2008) (63)
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer (2013) (63)
Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate‐specific antigen (PSA), stage, and grade trends in the PSA era (2001) (61)
Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. (1996) (61)
Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors. (1995) (59)
Negative pressure devices in the explanted penile prosthesis population. (1989) (59)
Prostate-specific antigen as a marker of disease activity in prostate cancer. (2002) (59)
Allelic loss on chromosome 6Q in primary prostate cancer (1999) (59)
Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. (2013) (58)
Patient selection for hemiablative focal therapy of prostate cancer (2009) (58)
Percent tumor involvement and risk of biochemical progression after radical prostatectomy. (2008) (57)
Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector (1997) (57)
Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease. (1994) (56)
Obesity and oncological outcome after radical prostatectomy: impact of prostate‐specific antigen‐based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center Databases (2008) (56)
Rupture of the deep dorsal vein of the penis during sexual intercourse. (1992) (56)
Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy (2008) (55)
Cadmium-induced neoplastic transformation of human prostate epithelial cells. (2002) (55)
Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. (2014) (54)
Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era (2001) (53)
Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. (2012) (52)
The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? (1996) (52)
Prognostic significance of DNA ploidy in carcinoma of prostate. (1989) (51)
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. (2009) (51)
Prostate cancer‐specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high‐risk factors (2007) (51)
Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization (1992) (51)
Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. (1999) (50)
Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours (1998) (50)
Radical prostatectomy vs radiation therapy and androgen‐suppression therapy in high‐risk prostate cancer (2012) (49)
Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. (1999) (48)
Prostate‐specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years (2007) (48)
Reference ranges for serum prostate-specific antigen in black and white men without cancer. (1998) (47)
Quantitative expression profile of PSGR in prostate cancer (2006) (47)
Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. (2000) (47)
The influence of ejaculation on serum levels of prostate specific antigen. (1997) (47)
Lidocaine Patch for Postoperative Analgesia After Radical Retropubic Prostatectomy (2009) (46)
Prostate-specific antigen levels in young white and black men 20 to 45 years old. (2000) (44)
Screening for familial and hereditary prostate cancer (2016) (44)
Use of Glycosylated Hemoglobin to Identify Diabetics at High Risk for Penile Periprosthetic Infections (1992) (43)
Variables in predicting survival based on treating "PSA-only" relapse. (2003) (43)
Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. (2003) (43)
Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. (2005) (43)
A novel human cancer culture model for the study of prostate cancer (2001) (42)
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. (1996) (42)
Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas. (1993) (42)
Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. (1995) (42)
Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. (2006) (42)
Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. (2012) (41)
Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy (2008) (41)
A review of surgical treatment of undescended testes with emphasis on anatomical position. (1988) (41)
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death (2010) (41)
Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. (2005) (41)
Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer* (2005) (40)
Contemporary hormonal management of advanced prostate cancer. (1998) (40)
Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. (2012) (40)
Rising PSA in nonmetastatic prostate cancer. (2007) (39)
p63 expression profile in normal and malignant prostate epithelial cells. (2002) (39)
Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. (1994) (39)
Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. (2004) (38)
Early prostate cancer: prevention, treatment modalities, and quality of life issues. (2003) (38)
Complications of therapy for testicular cancer. (1989) (37)
The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. (1998) (37)
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. (2006) (37)
Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer. (1995) (36)
Adenocarcinoma of the prostate: an expensive way to die (2002) (36)
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? (2009) (36)
Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. (1994) (36)
Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients (2004) (36)
Prostate‐specific antigen‐detected prostate cancer (Stage T1c): An analysis of whole‐mount prostatectomy specimens (1997) (35)
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? (2010) (35)
Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients (1997) (35)
Impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death (2010) (35)
The evolving definition of advanced prostate cancer. (2004) (35)
Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? (2002) (35)
Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. (1993) (35)
Emerging treatment options for patients with castration‐resistant prostate cancer (2012) (35)
Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. (2004) (34)
Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. (1999) (34)
Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients (2002) (34)
Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. (2002) (34)
The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. (2001) (34)
Masculinity Beliefs Predict Psychosocial Functioning in African American Prostate Cancer Survivors (2012) (34)
Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer* (2005) (34)
Prostate‐specific antigen screening among young men in the United States (2008) (33)
Mutations of the p16 gene product are rare in prostate cancer (1997) (33)
Improvements in pathologic staging for African‐American men undergoing radical retropubic prostatectomy during the prostate specific antigen era (2001) (33)
Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. (2008) (32)
Population screening for prostate cancer and emerging concepts for young men. (2003) (32)
A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer. (2014) (32)
Prostate specific antigen testing in men older than 75 years in the United States. (2006) (32)
Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer (2009) (31)
Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post‐operative sexual dysfunction (2013) (30)
Acute urinary retention associated with prostatic carcinoma. (1989) (30)
Relationship between body mass index and prostate cancer screening in the United States. (2007) (30)
African-American men with low-grade prostate cancer have higher tumor burdens: Results from the Duke Prostate Center (2012) (30)
Candida albicans corpora abscess following penile prosthesis placement. (1988) (30)
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. (2003) (29)
MOLECULAR ANALYSIS OF P16Ink4/CDKN2 AND P15Ink4B/MTS2 GENES IN PRIMARY HUMAN TESTICULAR GERM CELL TUMORS (1998) (29)
Molecular markers in prostate cancer: the role in preoperative staging. (2002) (29)
The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. (2004) (29)
ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. (2015) (29)
Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. (2004) (29)
Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. (1996) (28)
Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zone (2011) (28)
Sampling the spatial patterns of cancer: Optimized biopsy procedures for estimating prostate cancer volume and Gleason Score (2009) (28)
Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. (2012) (28)
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. (2011) (28)
Predictive value of digital rectal examination for prostate cancer detection is modified by obesity (2011) (28)
Proteomics in prostate cancer (2005) (28)
Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma. (1994) (27)
Prostate cancer: the new landscape (2009) (27)
Defining potency: A comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite (2008) (27)
A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. (2007) (27)
Clinical staging of prostate cancer: Reproducibility and clarification of issues (2001) (27)
Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? (2015) (27)
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease. (2011) (26)
Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. (2003) (26)
Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. (2007) (26)
Prostatic Alpha-Linolenic Acid (ALA) Is Positively Associated with Aggressive Prostate Cancer: A Relationship Which May Depend on Genetic Variation in ALA Metabolism (2012) (26)
Molecular implications of the antiandrogen withdrawal syndrome. (1995) (26)
Applications of neural networks in urologic oncology. (1998) (25)
Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors. (1997) (25)
Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours. (1997) (25)
Perineal seeding of prostate cancer as the only evidence of clinical recurrence 14 years after needle biopsy and radical prostatectomy: molecular correlation. (1998) (25)
Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. (2003) (25)
Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). (2011) (25)
Role of salvage lymph node dissection in prostate cancer (2016) (25)
Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature (2012) (25)
Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection. (1991) (25)
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. (2012) (25)
Baseline PSA as a predictor of prostate cancer‐specific mortality over the past 2 decades (2010) (24)
Testosterone in prostate cancer: the Bethesda consensus (2012) (24)
Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences (2012) (24)
Efficacy of radiographic chest imaging in patients with testicular cancer. (1994) (23)
p53‐dependent induction of heat shock protein 27 (HSP27) expression (2000) (23)
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl (2015) (22)
Utility of LHRH antagonists for advanced prostate cancer. (2014) (22)
Obese African‐Americans with prostate cancer (T1c and a prostate‐specific antigen, PSA, level of <10 ng/mL) have higher‐risk pathological features and a greater risk of PSA recurrence than non‐African‐Americans (2010) (22)
A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2) (2020) (22)
Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors (2000) (22)
Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. (2008) (21)
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. (2010) (21)
Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy (2012) (21)
Teleconferencing as a Method of Educating Men About Managing Advanced Prostate Cancer and Pain (1996) (21)
Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. (1994) (21)
Prognostic factors in low-stage nonseminomatous testicular cancer. (1996) (21)
Methylation of TFPI-2 gene is not the sole cause of its silencing. (2003) (20)
Experience with the AMS 600 malleable penile prosthesis. (1986) (20)
External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence (2004) (20)
Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma. (1991) (20)
Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy. (1990) (20)
Screening for prostate cancer in african americans (2000) (20)
Prognostic risk factors in low stage testicular germ cell tumors (1997) (20)
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. (2009) (19)
Most Gleason 8 Biopsies are Downgraded at Prostatectomy—Does 4 + 4 = 7? (2017) (19)
Pathological T2 sub‐divisions as a prognostic factor in the biochemical recurrence of prostate cancer (2010) (19)
Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls (2016) (19)
Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. (1995) (19)
Testicular cancer in blacks: A multicenter experience (1994) (19)
Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. (2013) (19)
Combined low‐dose flutamide plus finasteride vs low‐dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long‐term follow‐up (2009) (19)
Retroperitoneal fibrosis following radiotherapy for stage I testicular seminoma. (1992) (18)
Aneuploidy of Chromosome 9 and the Tumor Suppressor Genes p16INK4 and p15INK4B Detected by in situ Hybridization in Locally Advanced Prostate Cancer (2000) (18)
Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA (1996) (18)
Implementation of a web-based prostate cancer decision site. (2000) (18)
Factors predicting prostatic biopsy Gleason sum under grading. (2009) (18)
A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes. (2004) (18)
Rising PSA after local therapy failure: immediate vs deferred treatment. (1999) (17)
Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer (2012) (17)
Testicular cancer in blacks. A multicenter experience (1994) (17)
Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. (2005) (17)
Medical technologies for the diagnosis of prostate cancer (2007) (17)
Pelvic muscle rehabilitation in males following prostatectomy. (1998) (17)
Identifying appropriate patients for early salvage radiotherapy after prostatectomy. (2013) (17)
ANDROGEN DEPRIVATION THERAPY USING FINASTERIDE AND LOW DOSE FLUTAMIDE TO TREAT PSA FAILURE FOLLOWING THERAPY FOR CLINICALLY LOCALIZED ADENOCARCINOMA OF THE PROSTATE (CaP) (1999) (16)
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer. (2019) (16)
Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer (2017) (16)
Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis (1996) (16)
A Human Novel Gene DERPC Located on 16q22.1 Inhibits Prostate Tumor Cell Growth and Its Expression Is Decreased in Prostate and Renal Tumors (2002) (16)
Prostatitis. Sorting out the different causes. (1993) (16)
Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? (2017) (16)
Unnecessary mastectomy for gynecomastia in testicular cancer patient. (1992) (15)
Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. (2012) (15)
Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. (2011) (15)
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. (2010) (15)
Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects (2018) (15)
Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours. (2002) (15)
Treatment of PSA only recurrence of prostate cancer after prior local therapy. (2006) (15)
Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors. (1998) (15)
Distribution of Prostrate Cancer for Optimized Biopsy Protocols (2000) (15)
New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. (2011) (14)
3-D Model Supported Prostrate Biopsy Simulation and Evaluation (1998) (14)
Characterization of frequently deleted 6q locus in prostate cancer. (2006) (14)
Proper staging techniques in testicular cancer patients. (1995) (14)
The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer (2017) (14)
Contemporary Radical Prostatectomy (2011) (14)
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist (2018) (14)
Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma (2002) (13)
Will the future of health care lead to the end of the robotic golden years? (2014) (13)
A protocol to reduce self-reported pain scores and adverse events following lumbar punctures in older adults (2020) (13)
NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. (2012) (13)
Bilateral organ-limited amyloidosis of the distal ureter associated with osseous metaplasia and radiographic calcification. (1988) (13)
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy (2015) (13)
The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases (2010) (13)
Retroaortic left renal vein in testicular cancer patient: potential staging and treatment pitfall. (1992) (13)
Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. (2000) (12)
Combination hormonal therapy: a reassessment within advanced prostate cancer (2004) (12)
Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy. (2016) (12)
Management of Prostate Cancer in the Elderly. (2016) (12)
Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. (2001) (12)
Postoperative prostate‐specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases (2010) (12)
Prostate cancer in the late 1990s: hormone refractory disease options. (1999) (12)
Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer. (2004) (11)
The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. (2002) (11)
Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. (2011) (11)
Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey. (2013) (11)
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. (2010) (11)
PSA thresholds for prostate cancer detection. (1997) (11)
Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. (2009) (11)
Gossypiboma (retained surgical sponge) and recurrent bladder neck contracture after radical retropubic prostatectomy and bilateral pelvic lymph node dissection. (1997) (11)
Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains. (1989) (11)
Robot‐assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy (2009) (11)
Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. (2005) (11)
Prostate cancer in the Baby Boomer generation: results from CaPSURE. (2007) (11)
African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect? (2017) (11)
Update on outcomes research databases in prostate cancer 2006 (2006) (11)
Post-radical prostatectomy management options for positive surgical margins: argument for observation. (2009) (11)
Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. (1998) (11)
Initiation of salvage therapy for prostate cancer (2002) (10)
THE USE OF % FREE PSA (%fPSA) TO PREDICT PROSTATE CANCER PROBABILITIES: AN ELEVEN CENTER PROSPECTIVE STUDY USING AN AUTOMATED IMMUNOASSAY SYSTEM IN A POPULATION WITH NON-SUSPICIOUS DRE (1999) (10)
A decision aid for teaching limitations of prostate cancer screening. (2008) (10)
Prostate imaging based on rf spectrum analysis and nonlinear classifiers for guiding biopsies and targeting radiotherapy (2001) (10)
Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. (2009) (10)
Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. (2010) (10)
The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. (2007) (10)
A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. (2014) (10)
Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. (2003) (10)
Synchronous bilateral testis tumor: mixed germ cell and theca cell tumors. (1993) (10)
Predictors of extracapsular extension and positive margins in African American and white men. (2003) (10)
Renal milk of calcium: contraindication to extracorporeal shockwave lithotripsy. (1996) (10)
A novel neoplastic primary tumor-derived human prostate epithelial cell line. (2003) (10)
Re‐calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy (2009) (9)
670 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PROSTATE-SPECIFIC ANTIGEN CONTROL (2010) (9)
Biochemical recurrence of prostate cancer. (2003) (9)
Screening for prostate cancer in military populations. (2005) (9)
1184: How Long can Radical Prostatectomy (RP) Safely be Delayed? CPDR'S Experiences From 3324 Cases (2004) (9)
Visualization and Evaluation of Prostrate Needle Biopsy (1998) (9)
Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis. (2019) (9)
Traditional approaches to androgen deprivation therapy. (2011) (8)
The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data (2020) (8)
Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? (2014) (8)
Thymic hyperplasia in newly diagnosed testicular germ cell tumors. (1994) (8)
Prostate biopsy quantitative histology as a staging and prognostic factor. (2002) (8)
Age‐Specific Reference Ranges for Prostate Specific Antigen in Young Men: Retrospective Study from the National Defense University (2001) (8)
Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. (1996) (8)
Comparison of DRE and PSA in the Detection of Prostate Cancer. (2017) (8)
Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers (2022) (8)
Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. (2001) (8)
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System (2016) (8)
Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man. (1994) (7)
Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center (2002) (7)
Hormone naïve prostate cancer: predicting and maximizing response intervals (2015) (7)
Building an accurate 3D map of prostate cancer using computerized models of 280 whole-mounted radical prostatectomy specimens (2000) (7)
Prostate‐specific antigen velocity based risk‐adapted discontinuation of prostate cancer screening in elderly men (2011) (7)
For incontinence after prostatectomy, tap a diversity of treatments. (1994) (7)
Comparison of prostate biopsy protocols using 3D computer simulation (1998) (7)
1418: Can Hemodilution Explain the Lower PSA Concentrations Among Obese Men? (2007) (7)
Benign prostatic hyperplasia. (1993) (7)
Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist (2012) (7)
[Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy]. (1999) (7)
New tumor markers of testis cancer. (1998) (7)
Treating the biochemical recurrence of prostate cancer after definitive primary therapy. (2005) (7)
The impact of the “cisplatin era” of treatment on survival in testicular cancer (1991) (6)
High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy (2015) (6)
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. (2001) (6)
Outcome research: prostate cancer databases. (2002) (6)
Maximizing outcomes in genitourinary cancers across the treatment continuum (2011) (6)
Diagnosis, staging, and risk factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. (2011) (6)
Primary malignant melanoma of the scrotum (2006) (6)
NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. (2014) (6)
Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer. (2011) (6)
Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer? (2007) (6)
Prostate cancer: an evolving paradigm. (2010) (6)
Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer. (1993) (6)
Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer. (1997) (5)
Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low‐volume tumors (2010) (5)
Review: Risk stratification in the hormonal treatment of patients with prostate cancer (2009) (5)
Managing advanced prostate cancer with Viadur (leuprolide acetate implant). (2001) (5)
Utility of a 3-Dimensional Transrectal Ultrasound-guided Prostate Biopsy System for Prostate Cancer Detection (2009) (5)
TWENTY‐FIVE YEAR EVOLUTION OF MEDICAL HORMONAL THERAPY FOR PROSTATE CANCER (2009) (5)
Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate (2006) (5)
Awareness, concern, and communication between physicians and patients on bone health in cancer (2014) (5)
Targeting the androgen receptor--theory and practice. (2011) (5)
Controversies in the treatment of prostate cancer with maximal androgen deprivation. (1995) (5)
Epidemiology and screening for prostate cancer. (1997) (5)
The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database (2010) (5)
Predicting non-organ-confined prostate cancer in men diagnosed after 2000 (2010) (5)
Active surveillance for African-American men with prostate cancer: of course! Pro. (2014) (5)
Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. (2013) (5)
Management of the patient with a rising PSA alone. (2006) (5)
An important goal of prostatectomy: minimizing incontinence. (1994) (5)
Patient selection for experimental adjuvant therapy after radical prostatectomy. (1996) (4)
ANDROGEN DEPRIVATION WITH SALVAGE SURGERY FOR RADIORECURRENT PROSTATE CANCER: RESULTS AT 5-YEAR FOLLOWUP (1998) (4)
Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression (2022) (4)
Optimization of prostate biopsy (1999) (4)
Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard. (2012) (4)
Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2 (CAPS2). (2018) (4)
Refusal of cancer treatment in testicular cancer patients. (1989) (4)
Systemic strategies for prostate cancer. (2007) (4)
Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? (2008) (4)
Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction. (2000) (4)
Radiotherapy: Secondary malignancies after prostate cancer treatment (2010) (4)
Indications and practice with androgen deprivation therapy. (2011) (4)
Hormonal therapy options for prostate‐specific antigen‐only recurrence of prostate cancer after previous local therapy (2005) (4)
Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults (2021) (4)
Diagnostic accuracy of prostate needle biopsy (2002) (4)
Refusal of cancer therapy in testicular cancer: Recognizing and preventing a significant problem (1990) (4)
Original Articles PRETREATMENT TOTAL TESTOSTERONE LEVEL PREDICTS PATHOLOGICAL STAGE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY (2003) (3)
Focusing on testosterone. (2011) (3)
Prostate Cancer Satisfaction and Regret after Open Retropubic or Robot-Assisted Laparoscopic Radical Prostatectomy (2008) (3)
Relationship Between Depression/Anxiety and Cognitive Function Before and 6 Weeks After Major Non-Cardiac Surgery in Older Adults (2020) (3)
Leuprolide Acetate (2020) (3)
Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. (2012) (3)
Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer. (2015) (3)
INDEPENDENT PREDICTORS FOR DISSATISFACTION WITH AND REGRET OF TREATMENT CHOICE AFTER RADICAL PROSTATECTOMY (2008) (3)
Benign prostatic hyperplasia. New concepts in the 1990s. (1993) (3)
DOES PATHOLOGICAL GLEASON SCORE RE-REVIEW BY A MODERN PATHOLOGIST IMPROVE RISK STRATIFICATION RELATIVE TO HISTORICAL GLEASON SCORE? (2009) (3)
866 PROSTATE-SPECIFIC ANTIGEN AND SERUM ALKALINE PHOSPHATASE LEVELS IN PROSTATE CANCER PATIENTS RECEIVING DEGARELIX OR LEUPROLIDE (2010) (3)
POS-03.126: SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men (2007) (3)
Reply: To PMID 25432832. (2014) (3)
No-Shows in Adult Urology Outpatient Clinics: Economic and Operational Implications (2020) (3)
Novel techniques for the treatment of localized prostate cancer: Evidence of efficacy? (2007) (3)
1915 NADIA PROSVUE™ SLOPE IDENTIFIES PATIENTS AT GREATLY REDUCED RISK FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY (2011) (3)
OBESITY AS A PREDICTOR OF ADVERSE OUTCOME ACROSS BLACK AND WHITE RACE: RESULTS FROM THE SEARCH AND DUKE PROSTATE CENTER DATABASES (2008) (2)
External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database (2010) (2)
Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer (2020) (2)
Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer. (2022) (2)
Rapidly progressing adenocarcinoma of the prostate presenting as prostatitis. (2002) (2)
Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial (2014) (2)
Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist. (2010) (2)
An analysis of watchful waiting for prostate cancer and factors to predict secondary treatment (2003) (2)
POD-05.09: Predicting Unilaterality of Prostate Cancer on Biopsy: Sextant Versus Extended (2009) (2)
Population Screening for Prostate Cancer and Early Detection (2016) (2)
Prostate cancer: Active surveillance in African American men (2013) (2)
Retroperitoneal lymphadenectomy. (1993) (2)
Testicular tumour. (1992) (2)
Best screening tests for prostate cancer. (1998) (2)
The Department of Defense center for prostate disease research. (2002) (2)
Epidemiology of prostate cancer, its treatment and outcome: introduction of the Department of Defense Center for Prostate Disease Research (DOD-CPDR) multicenter prostate cancer database with 307,931 records on 13,878 men (2002) (2)
Probability of cancer detection with optimized prostate biopsy protocols (2001) (2)
OLDER MEN ASSOCIATED WITH ADVANCED DISEASE AND POOR OUTCOME: AN ANALYSIS OF 14601 PROSTATE CANCER MEN IN DUKE PROSTATE CENTER (2008) (2)
335 DIABETES MELLITUS AND THE RISK OF HIGH-GRADE PROSTATE CANCER: RESULTS FROM THE DUKE PROSTATE CENTER (2011) (2)
1992 New York-Tidewater chapters History of Military Medicine Essay Award recipient. James Claude Kimbrough: the father of modern U.S. Army urology. (1993) (2)
Impact of flaxseed supplementation and dietary fat restriction on prostate cancer proliferation and other biomarkers: Results of a Phase II randomized controlled trial (RCT) using a presurgical model (2007) (2)
Low-risk prostate cancer patient: active treatment. (2005) (2)
Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution. (2015) (2)
SAY NO TO THE US PREVENTATIVE TASK FORCE RECOMMENDATION TO NO LONGER OFFER PROSTATE CANCER SCREENING AFTER AGE 75 (2009) (2)
Radical prostatectomy and cryotherapy--some answers, more questions. (1997) (2)
Prognostic impact of post-prostatectomy PSA slope determined with a novel, nucleic acid detection immunoassay (NADiA ProsVue) for total PSA. (2011) (2)
High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care. (2015) (2)
When should we pull the trigger for post-radical prostatectomy radiotherapy? (2012) (2)
3D model supported virtual environment for prostate disease interpretation and biopsy design (1998) (2)
Yes or no to local therapy for oligometastatic prostate cancer? (2018) (2)
Tumor volume, tumor percentage involvement or prostate volume: Which is predictive of PSA recurrence? (2009) (2)
Benign Prostatic Hyperplasia: New Concepts for the Millennium (1999) (2)
THE INFLUENCE OF MEDICARE REFORM ON THE UTILIZATION OF ANTI-ANDROGENS IN A COHORT OF PATIENTS WITH OF PROSTATE CANCER IN THE UNITED STATES (2008) (2)
Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. (2006) (2)
NCCN Prostate Cancer Early Detection Panel Members (2001) (1)
THE EPIDEMIOLOGY OF PROSTATE CANCER IN JAMAICA: EDITORIAL COMMENT (1998) (1)
Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance (2013) (1)
EVALUATION OF REVERSE TRANSCRIPTASE (RT)-POLYMERASE CHAIN REACTION (PCR)-PROSTATE SPECIFIC ANTIGEN (PSA) ASSAY IN EPITHELIAL CELLS ISOLATED FROM PERIPHERAL BLOOD OF PROSTATE CANCER (CaP) PATIENTS (1999) (1)
Prostate Biopsy Protocols: 3D Visualization-Based Evaluation and Clinical Correlation (2001) (1)
Prostatitis and Urethritis (1999) (1)
Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer. (2012) (1)
Prostate-specific antigen screening and prostate cancer mortality: implications of a randomized European study (2009) (1)
LOW GRADE NON-HODGKIN'S LYMPHOMA AFTER HIGH GRADE NON-HODGKIN'S LYMPHOMA IN A CHILD WITH ATAXIA TELEANGIECTASIA. AUTHOR'S REPLY (1994) (1)
Abstract A95: Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: A relationship which may depend on genetic variation in ALA metabolism (2012) (1)
Acute Presentation of Previously Unrecognized Congenital UPJ Obstruction 5 Weeks after Radical Retropubic Prostatectomy. (2019) (1)
Refusal in testicular cancer patients: implications for surveillance. (1992) (1)
Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment. (2010) (1)
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer (2008) (1)
PSA Recurrence of Prostate Cancer (2006) (1)
Secondary screening tests for prostate cancer: is more information better? Which test is best? (2020) (1)
How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer. (2019) (1)
Managing Prostate Cancer Surgical Patients during the COVID-19 Pandemic: A Brief Report of the Duke Cancer Institute's Initial Experience. (2020) (1)
IS PSA A POOR PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMY IN OBESE MEN (2008) (1)
PRE-TREATMENT FACTORS PREDICTIVE OF POSITIVE SURGICAL MARGIN IN CONTEMPORARY RADICAL PROSTATECTOMIES (2008) (1)
COMPREHENSIVE PREOPERATIVE EVALUATION AND REPAIR OF INGUINAL HERNIAS AT THE TIME OF OPEN RADICAL RETROPUBIC PROSTATECTOMY DECREASES RISK OF DEVELOPING POSTPROSTATECTOMY HERNIA (2012) (1)
Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. (2010) (1)
RECALIBRATION AND EXTERNAL VALIDATION OF AN EXISTING NOMOGRAM TO PREDICT AGGRESSIVE RECURRENCES AFTER RADICAL PROSTATECTOMY (RP) (2009) (1)
Conservative Management of a Pyelovenous Fistula After a Renal Gunshot Wound (2019) (1)
Molecular Mechanisms of Castrate-Resistant Prostate Cancer. (2022) (1)
Loss of maspin expression in prostate cancer induced by a P53- and HER-2- pathway/overexpression profiling by whole-mount derived tissue microarrays (2003) (1)
Siog (international society of geriatric oncology) localised prostate cancer guidelines proposals in senior adult men (2008) (1)
What to order from the prostate cancer treatment menu? (2012) (1)
ANEUPLOIDY FOR CHROMOSOME 9 DETECTED BY IN SITU HYBRIDIZATION (ISH) CORRELATES WITH POOR PROGNOSIS IN PROSTATE CANCER (1999) (1)
PD30-09 RANDOMIZED CONTROLLED TRIAL OF A 6-MONTH LOW CARBOHYDRATE INTERVENTION ON WEIGHT AND DISEASE PROGRESSION IN MEN WITH RECURRENT PROSTATE CANCER: CARBOHYDRATE AND PROSTATE STUDY 2 (CAPS2) (2019) (1)
Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men. (1991) (1)
Cellular functions and pathways affected by PCGEM1, a prostate-specific gene associated with African-American prostate cancer patients (2004) (1)
Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. (2008) (1)
Are we overtreating prostate cancer? (2008) (1)
720 TIME TO PROGRESSION IN PATIENTS WITH PROSTATE CANCER: A COMPARISON OF CONTINUOUS DEGARELIX VERSUS DEGARELIX FOLLOWING LEUPROLIDE TREATMENT (2011) (1)
Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. (2010) (1)
BODY MASS INDEX AND PROSTATE-SPECIFIC ANTIGEN AS A PREDICTOR OF ADVERSE PATHOLOGY AND BIOCHEMICAL RECURRENCE FOLLOWING RADICAL PROSTATECTOMY (2009) (1)
[Clinical stage I mature teratoma of the testis--retroperitoneal lymphadenectomy or surveillance?]. (1997) (1)
Abstracts of the 15th Congress of the European Society for Urological Research, Istanbul, October 5–7, 2000 (2000) (1)
SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY) (2008) (1)
441: Pathologic Variables and Recurrence Rates as Related to Obesity and Race in Men with Prostate Cancer Undergoing Radical Prostatectomy (2004) (1)
PD08-10 SOCIAL MEDIA PRESENCE OF UNITED STATES ACADEMIC UROLOGY RESIDENCY PROGRAMS (2019) (1)
Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. (2008) (1)
Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection. (1998) (1)
1782: Utilization of Radical Prostatectomy in Elderly men in the United States (2007) (1)
Model-supported virtual environment for prostate cancer pattern analysis (1999) (1)
1724 INITIAL PSA >= 1.5 NG/ML IN MEN =< 50 YEARS OLD PREDICTS A SUBSEQUENT HIGHER RISK OF PROSTATE CANCER (2010) (1)
Re: p53 protein and gene alterations in pathological stage C prostate carcinoma. (1998) (1)
The clinical significance of a PSA nadir > 0.2 to patients with a rising post-operative or post-radiation PSA treated with androgen deprivation (2005) (1)
1003 ROLE OF OXIDATIVE STRESS IN A RAT MODEL OF RADIATION-INDUCED ERECTILE DYSFUNCTION (2012) (1)
Development and evaluation of optimal prostate biopsy protocols for individual groups of patients (2004) (1)
New data, new paradigms for treating patients with prostate cancer: introduction. (2011) (1)
Are COVID-19 Delays a Basis for Concern? Can We Use This for Future Good? (2020) (1)
Preoperative Predictors of Pathologic Stage T2a in Low-Risk Prostate Cancer: Implications for Focal Therapy (2012) (1)
Does Robotic Prostatectomy Increase the Need for Adjuvant Radiation Therapy? The Impact of Choice of Surgery and Pretreatment Disease Characteristics on Adjuvant Indications (2008) (1)
A Case of Fatal Clostridial Necrotizing Fasciitis After Radical Prostatectomy. (2018) (1)
LATERAL PROSTATE BIOPSYS INCREASE THE DETECTION RATE OF PROSTATE CANCER IN 3-D COMPUTER SIMULATED PROSTATE MODELS (1999) (1)
EDITORIAL: PROSTATE CANCER 1997-PRACTICING WHAT WE PREACH (1997) (1)
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone‐Refractory Prostate Carcinoma: ECOG‐ACRIN Cancer Research Group (E1898) Trial (2017) (1)
20 Future Directions in Prostate Cancer Diagnosis (0)
1027: Tumor Percentage of Prostatectomy Specimens is an Independent Risk Factor for Biochemical Recurrence and Negative Clinicopathological Variables (2007) (0)
Refusal intesticular cancer patients: implications forsurveillance (1992) (0)
1889: Utilization of Prostate Specific Antigen Testing in Young Men in the United States (2007) (0)
PSA recurrence of prostate cancer: Update 2006 (2006) (0)
470: Changing Face of Prostate Cancer in the PSA-Era: Results from the CPDR National Database (2004) (0)
Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database. (2023) (0)
Support of the Center for Prostate Disease Research at Walter Reed Army Institute of Research. (1994) (0)
2031 LONG TERM OUTCOME OF MEN TREATED BY RADICAL PROSATECTOMY WITH PSA &[LE]4.0 NG/ML (2010) (0)
Rising PSA Level in an Anxious Postprostatectomy Patient. (2016) (0)
Editorial Comment. (2019) (0)
The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer (2008) (0)
Artificial Neural Networks in Urologic Oncology (2001) (0)
Prostate Cancer Screening in African-American Men (2018) (0)
The long-running disparity in early detection and treatment of prostate cancer in African American men. (2022) (0)
Commentary (Moul): The Role of Cytotoxic Chemotherapy in Prostate Cancer (2006) (0)
Editorial Comment: Prospective Evaluation of Prostate Specific Antigen and Prostate Specific Antigen Density in the Detection of Carcinoma of the Prostate (1997) (0)
Editorial Comment. (2017) (0)
1744: Using Prostate Specific Antigen and Prostate Specific Antigen Velocity to determine when to stop Prostate Cancer Screening in Men Older than 70 Years (2007) (0)
CORRELATION OF PRE-BIOPSY PSA LEVELS WITH TUMOR VOLUME AND SURGICAL MARGIN STATUS IN STAGE T1C PATIENTS (1999) (0)
528: Prostate Specific Antigen Testing in Men Over 75 (2005) (0)
DYNAMIC SCREENING FOR PROSTATE CANCER IMPROVES AUCs RELATIVE TO STATIC SCREENING USING A SINGLE PSA THRESHOLD – RESULTS FROM THE DUKE PROSTATE CENTER (2008) (0)
334 COST-EFFECTIVENESS OF CHEMOPREVENTION WITH FINASTERIDE FOR PROSTATE CANCER VARIES ACROSS SUBGROUPS DEFINED BY FAMILY HISTORY AND GENETIC POLYMORPHISMS (2010) (0)
960: Is Race a Prognostic Factor of Prostate Tumor Burden and Outcome in the PSA Era: The Duke Experience 2006 (2006) (0)
863: Racial Difference in Location, Number and Volume of Prostate Cancerbased on 3-Dimensional Reconstructed Radical Prostatectomy Specimens (2004) (0)
Treating the Troops: A Model for Battling Health-Care Disparities (2006) (0)
Image guidance for post-prostatectomy radiotherapy: Are we missing the mark? (2013) (0)
MOLECULAR DETERMINATION OF SURGICAL MARGINS USING FOSSA BIOPSIES AT RADICAL PROSTATECTOMY: EDITORIAL COMMENT (1999) (0)
Prognostic risk factors in low stage testicular nonseminomatous germ cell tumors (NSGCT) (1997) (0)
OVER HALF OF CONTEMPORARY CLINICAL GLEASON 8 ON PROSTATE BIOPSY ARE DOWNGRADED AT RADICAL PROSTATECTOMY: MP33‐18 (2017) (0)
Editorial Comment. (2017) (0)
Preoperatiove prostate cancer volume estimation based on clinically correlated needle biopsy simulation (2002) (0)
DYNAMIC SCREENING DETECTS PROSTATE CANCER (PC) EARLIER AND WOULD LEAD TO IMRPROVED CANCER CONTROL: RESULTS FROM THE DUKE PROSTATE CENTER AND THE SEARCH DATABASE (2008) (0)
1638 UNILATERAL PROSTATE CANCER ANALYIS OF PREDICTORS IN SEARCH AND DUKE PROSTATE CENTER DATABASES (2012) (0)
Immunization with TG4010 appears biologically active in prostate cancer. Comment (2005) (0)
Moderated Poster SessionModerated Poster Session 16: PCA, LocalizedMP-16.17: Radical Prostatectomy over the Past Two Decades: Duke's Experience in 4196 Cases (2009) (0)
Editorial Comment. (2016) (0)
Cancer-Specific M ortality A fter S urgery o r R adiation f or Patients W ith C linically L ocalized P rostate C ancer M anaged During t he P rostate-Specifi c A ntigen E ra (2003) (0)
Image Guidance Affects Biochemical Outcome for Postprostatectomy Radiation Therapy (2013) (0)
Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men (2009) (0)
MUTATIONAL ANALYSIS OF MASPIN GENE IN PROSTATE CANCER CELLS (1999) (0)
How Can We Effectively Address the Medical and Psychological Concerns of Survivors of Pelvic Malignancies? (2017) (0)
CLINICAL UROLOGY: LETTER TO THE EDITORRE: DETECTION OF CIRCULATING PROSTATE SPECIFIC ANTIGEN EXPRESSING PROSTATIC CELLS IN THE BONE MARROW OF RADICAL PROSTATECTOMY PATIENTS BY SENSITIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (2000) (0)
3D Conformal and Intensity Modulated Radiotherapy to the Prostate Bed have Similar Biochemical Outcomes (2011) (0)
MP16-13 CAN WE USE THE PROSTATE HEALTH INDEX TO AVOID A PROSTATE BIOPSY IN AFRICAN AMERICAN MEN? (2022) (0)
Randomized head-to-head prospective study of pharmacokinetic and pharmacodynamic properties of leuprolide acetate formulations: 7.5 mg single depot subcutaneous vs 7.5 mg intramuscular microsphere. (2015) (0)
Utilizing Biopsy-Based Genomic Assays to Risk-Stratify Patients (2017) (0)
Novel techniques for the treatment of localized prostate cancer: Evidence of efficacy? (2007) (0)
Evidence to Support that Serial Screening Decreases Prostate Cancer-Specific Mortality (2005) (0)
1307 AFRICAN AMERICAN MEN WITH LOW-GRADE PROSTATE CANCER HAVE HIGHER TUMOR BURDENS: RESULTS FROM DUKE PROSTATE CENTER (2011) (0)
OBESE MEN HAVE LARGER AND HIGHER-GRADE TUMORS: AN ANALYSIS OF THE DUKE PROSTATE CENTER DATABASE (2008) (0)
Health policy: Health-care implications of resident duty-hour restrictions (2009) (0)
1204 HEIGHT AND THE RISK FOR AGGRESSIVE PROSTATE CANCER AT THE TIME OF BIOPSY–RESULTS FROM THE DUKE PROSTATE CENTER DATABASE (2011) (0)
Longitudinal outcomes following implementation of baseline PSA risk stratification of men in their forties (2022) (0)
Chapter 1 – Population Screening for Prostate Cancer and Early Detection in High-risk African American Men* (2003) (0)
Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs. (2022) (0)
604: Immunohistochemical Analysis of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Expression in Prostate Cancer (2004) (0)
Rebuttal to Dr. Stock (2008) (0)
PSA Recurrence of Prostate Cancer : Published on Cancer Network (2017) (0)
Melanomas that defy clinical recognition. (1992) (0)
Hot topic of cancer survivorship and the ‘seven deadly sins’ (2015) (0)
1666: Serum Proteomic Profiling Using Seldi-Tof for Prostate Cancer Diagnosis (2004) (0)
The Number of High-Risk Factors and the Risk of Prostate Cancer-Specific Mortality Following Radical Prostatectomy or Brachytherapy (2011) (0)
MP15-06 AFRICAN-AMERICAN MEN WITH LOW-RISK PROSTATE CANCER ARE CANDIDATES FOR ACTIVE SURVEILLANCE: THE WILL-ROGERS EFFECT? (2016) (0)
Supplement Article Traditional Approaches to Androgen Deprivation Therapy (2011) (0)
MP09-18 LONGITUDINAL OUTCOMES FOLLOWING IMPLEMENTATION OF BASELINE PSA RISK STRATIFICATION OF MEN IN THEIR FORTIES (2022) (0)
The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data. (2019) (0)
Northeastern Section of the AUA 72nd Annual Meeting Abstracts (2020) (0)
Prostate specific gen pcgem1 and methods for its use for the detection, treatment and prevention of prostate cancer (2000) (0)
MP17-10 DEVELOPMENT AND UTILIZATION OF AN AT HOME URINE EXOSOME BIOMARKER COLLECTION TEST KIT TO SUPPORT UROLOGIC TELEHEALTH (2023) (0)
Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States. (2019) (0)
MP14-13 WEIGHING IN ON ACTIVE SURVEILLANCE: IMPACT OF OBESITY ON PATIENT COUNSELING (2015) (0)
Re-thinking How We Use Prostate Health Index for African American Men. (2022) (0)
Histopathological and biological prognostic risk factors in low stage testicular nonseminomatous germ cell tumors (1999) (0)
MP-16.18: Real-Time Personalized Medicine for Prostate Cancer: Duke's Experience (2009) (0)
Letters to the Editor/ErrataRE: THE ECONOMIC BURDEN OF METASTATIC AND PROSTATE SPECIFIC ANTIGEN PROGRESSION IN PATIENTS WITH PROSTATE CANCER: FINDINGS FROM A RETROSPECTIVE ANALYSIS OF HEALTH PLAN DATA (2004) (0)
1050: Pre- and Post-Surgery Factors Affecting the Outcomes of Patients with Intermediate Risk Prostate Cancer (2004) (0)
Molecular Genetics of Testicular Cancer (1997) (0)
Prostate Cancer (2020) (0)
What Factors Influence Referral for Postoperative Radiation Therapy for Prostate Cancer (2008) (0)
Advances in Brief PSGR , a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor , Is Overexpressed in Prostate Cancer 1 (2000) (0)
Bone Complications in Prostate Cancer: Current and Future Role of Bisphosphonates (2005) (0)
Isolated high grade prostatic intraepithelial neoplasia may not predict future prostatic malignancy (2002) (0)
Future Directions in Prostate Cancer Diagnosis (2008) (0)
Investigator-initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF Prostate Cancer Clinical Trials Consortium. (2011) (0)
Expression during Prostate Cancer Progression Exhibits Cell Growth Inhibitory Function and Decreased PMEPA 1 , an Androgen-regulated NEDD 4-binding Protein (2003) (0)
1947 AFRICAN-AMERICAN RACE IS AN INDEPENDENT PREDICTOR OF PROSTATE CANCER SPECIFIC DEATH AFTER PSA RECURRENCE (2010) (0)
Editorial Comment. (2015) (0)
Castration-resistant prostate cancer: Why should urologists care? (2016) (0)
Editorial comment. (2010) (0)
Intracranial metastatic adenocarcinoma of the prostate presenting as visual disturbance. (1997) (0)
Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy. (2010) (0)
RACIAL DIFFERENCES IN CLINICALLY LOCALIZED PROSTATE CANCERS OF BLACK AND WHITE MEN: EDITORIAL COMMENT (1998) (0)
Commentary (Moul): Prostate Cancer Risk Assessment Program (1999) (0)
PREDICTING NON-ORGAN CONFINED PROSTATE CANCER AFTER THE YEAR 2000 (2009) (0)
1839 RISK STRATIFICATION FOR PROSTATE CANCER USING AGE-SPECIFIC PSA QUARTILES (2010) (0)
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 (2017) (0)
PREDICTORSOF PATIENT-REPORTEDOUTCOMES COMPLETION IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY AND ASSOCIATIONS BETWEEN RESPONSE FREQUENCY AND FUNCTIONAL OUTCOMES (2022) (0)
“DON'T LET THEM TOUCH ME?” TRAINEES DO NOT NEGATIVELY IMPACT THE INSTITUTIONAL LEARNING CURVE FOR ROBOTIC PROSTATECTOMY AS CHARACTERIZED BY OPERATIVE TIME, ESTIMATED BLOOD LOSS AND POSITIVE SURGICAL MARGIN RATE (2008) (0)
235: Evaluation of Serum Seldi-Tof Proteomic Information and Tumor Volume in Prostate Cancer Patients (2005) (0)
Head-to-head pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprorelin acetate formulations in male patients. (2017) (0)
OBESITY DOES NOT IMPACT SURGICAL MARGIN STATUS IN ROBOTIC PROSTATECTOMY (2009) (0)
DNA ploidy in nonseminomatous germ cell testicular tumor. (1994) (0)
Vol. 35, 1999 (1999) (0)
Supplement Article Indications and Practice With Androgen Deprivation Therapy (2011) (0)
Inappropriate surgery for testicular cancer. (1992) (0)
MP-10.20: Follow-up on patients with small prostate cancer following radical prostatectomy at Walter Reed Army Medical Center (2006) (0)
615: Pathological Gleason 7 in 1323 Men Receiving Radical Prostatectomy: The Necessity to Separate the Gleason Patters 3+4 and 4+3? (2007) (0)
445: Prostate Cancer Mortality After Radical Prostatectomy or Radiation Therapy in Men with Clinically Localized Prostate Cancer (2004) (0)
Subject Index Vol. 35, 1999 (1999) (0)
Chapter 4 Systemic treatment of recurrence after local therapies (2010) (0)
Original article Predictors of extracapsular extension and positive margins in African American and White men (2003) (0)
Prostate-specific antigen as a marker of disease activity in prostate cancer. (2002) (0)
1106: Quantitative Expression Characteristics of a Panel of Prostate Cancer Genes in Matched Benign and Neoplastic Prostate Cells of Patients with “Aggressive” and “Non-Aggressive” Cancer (2004) (0)
ERECTILE DYSFUNCTION IN THE PROSTATE CANCER PATIENT (1999) (0)
Innovations in urology from military medicine. (2009) (0)
425: Quantitative Expression Profile of PSGR in Prostatic Epithelial Cells of Benign and Malignant Prostate (2004) (0)
635: Age and Race-Based PSA Reference Ranges to Detect Curable Prostate Cancer (2004) (0)
Prostate cancer 1997--practicing what we preach. (1997) (0)
Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen. (2022) (0)
Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults (2021) (0)
1102: Gene Expression Signatures in Benign and Malignant Epithelial Cells of Prostate Cancer Patients with “Aggressive” and “Non-Aggressive” Disease (2004) (0)
SMALL PROSTATE SIZE PREDICTS BIOCHEMICAL PROGRESSION AFTER RADICAL PROSTATECTOMY (2008) (0)
PD11-04 THE LIMITED UTILITY OF PROSTATE HEALTH INDEX IN AFRICAN AMERICAN MEN WITH A PSA 4-10 (2022) (0)
Use of PSA Slope to Guide Adjuvant Radiotherapy in Post-Prostatectomy Prostate Cancer has Potential to be Cost Effective (2014) (0)
DECREASING OVERTREATMENT OF LOCALIZED PROSTATE CANCER WITH RADICAL PROSTATECTOMY: 10‐YEAR TRENDS: MP64‐13 (2017) (0)
663 ADJUVANT VERSUS SALVAGE RADIATION THERAPY FOR PROSTATE CANCER AND THE RISK OF DEATH (2010) (0)
Neoadjuvant Radiotherapy plus Prostatectomy for High Risk Prostate Cancer (2011) (0)
Author reply (0)
Aggressive prostate cancer masquerading as acute prostatitis. (2021) (0)
Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen–Based Risk Assessment in Younger Men. Eur Urol 2012;61:8–9 (2012) (0)
Editorial Commentary. (2021) (0)
Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy? (2006) (0)
1080: Mechnanisms of Hepsin Function and Expression in Prostate Cancer Cells (2004) (0)
The type of ADT may matter for testosterone recovery. (2021) (0)
Use of PSA threshold to identify an increased 4-year risk of a prostate cancer diagnosis in U.S. men. (2009) (0)
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 Review (2017) (0)
POD-4.12: Stratification of Age and Gleason Grade as a Model for Selection of Optimal Candidates for Definitive Therapy of Localized Prostate Cancer (2008) (0)
NADIA® Psa Slope Impacts Urologists’ Recommendations for Adjuvant Radiotherapy for Prostate Cancer Patients with High-Risk Pathology Following Radical Prostatectomy (2014) (0)
OUTCOMES OF RADICAL PROSTATECTOMY IN ELDERLY MEN IN THE UNITED STATES (2008) (0)
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database. (2012) (0)
2237 DOES LONG-TERM ASPIRIN USE LOWER SERUM PSA LEVELS? - RESULTS FROM THE DUKE PROSTATE CENTER (2012) (0)
400: Celluar Functions of PCGEM1, a Prostate-Specific Gene Associated with African American Prostate Cancer Patients (2004) (0)
Outcomes research section Outcome research: prostate cancer databases (2002) (0)
Editorial comment. (2015) (0)
Chapter 8 Molecular progression of prostate cancer (1999) (0)
New tumor markers of testis cancer : Testis cancer (1998) (0)
Should elderly men be screened for prostate cancer (2008) (0)
How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care. (2022) (0)
Urinary microbiota and prostatic diseases: the key for the lock? A systematic review. (2022) (0)
Salvage Radiation in Men with PSA Failure following Radical Prostatectomy and the Risk of Death (2010) (0)
The urology perspective on expanding androgen-targeted treatments for men with castration-resistant prostate cancer. (2014) (0)
Editorial comment. (2014) (0)
Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 1 Review (2017) (0)
Mature, clinical stage I testicular teratoma: retroperitoneal lymphadenetomy or surveillance? (1997) (0)
Simulated prostate biopsy: prostate cancer distribution and clinical correlation (2000) (0)
NOMOGRAM BASED ON SEXTANT POSITIVE BIOPSY CORES, GLEASON SUM AND PRE-BIOPSY PSA TO PREDICT ORGAN CONFINEMENT IN RADICAL PROSTATECTOMY PATIENTS-A CENTER FOR PROSTATE DISEASE RESEARCH (CPDR) MULTI-CENTER STUDY (1999) (0)
Assessment of current practices among physicians and awareness and concern among patients for bone health in cancer. (2011) (0)
POD-4.08: Racial Disparity Remains Associative with Advanced Prostate Cancer in late PSA-era: An Analysis of 2784 Radical Prostatectomies After 2000 (2008) (0)
Supplement Article Targeting the Androgen Receptor—Theory and Practice (2011) (0)
Development of Internet-Accessible Prediction Models for Prostate Cancer Diagnosis, Treatment, and Follow-Up (2003) (0)
2029 SHOULD A DIGITAL RECTAL EXAMINATION BE OPTIONAL FOR EARLY DETECTION OF PROSTATE CANCER IN OBESE MEN (2011) (0)
African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center. (2012) (0)
1331 PREOPERATIVE ERECTILE DYSFUNCTION IS ASSOCIATED WITH LARGER TUMOR VOLUMES -AN ANALYSIS FROM THE DUKE PROSTATE CENTER DATABASE (2011) (0)
First International Workshop on Focal Therapy and Imaging of Prostate Cancer (2018) (0)
Early results of RTOG protocol 99-06 for bladder cancer 'encouraging'. Comment (2005) (0)
THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) NOMOGRAM FOR RISK STRATIFICATION IN INTERMEDIATE RISK GROUP OF MEN WITH PROSTATE CANCER: VALIDATION IN THE DUKE PROSTATE CENTER (DPC) DATABASE (2009) (0)
UNILATERALITY OF EARLY STAGE LOCALIZED PROSTATE CANCER CANNOT BE RELIABLY PREDICTED BY ROUTINE PROSTATE BIOPSY (2008) (0)
PROLIFERATIVE ACTIVITY IN PROSTATIC INTRAEPITHELIAL NEOPLASIA OF PATIENTS TREATED WITH ANDROGEN BLOCKADE (1999) (0)
PSA THRESHOLDS FOR PROSTATE CANCER DETECTION. AUTHORS' REPLY (1997) (0)
Leuprolide acetate (once-yearly implant): profile report (2012) (0)
Correction: A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2) (2021) (0)
Prostate Cancer : diagnosis and surgical treatment (2003) (0)
MP-16.16: Determining Follow Up after Radical Prostatectomy: A Predictive Model to Improve Efficiency and Improve Patient Care (2009) (0)
International society of geriatric oncology (SIOG) proposal of guidelines for advanced prostate cancer in senior adults (2008) (0)
Advances in Brief Percentage of Embryonal Carcinoma and of Vascular Invasion Predicts Pathological Stage in Clinical Stage I Nonseminomatous Testicular Cancer 1 (2007) (0)
Risk Factors for Clinical Progression and Prostate Cancer Death After Initial Rising PSA (2017) (0)
DELAYED PSA RECURRENCE AFTER RADICAL PROSTATECTOMY: HOW TO IDENTIFY PATIENTS AT RISK AND THEIR CLINICAL OUTCOMES? (2009) (0)
229: Frequent Overexpression of ETS-related Gene (ERG) in Prostate Cancer Transcriptome Reveals its Diagnostic and Prognostic Potential (2005) (0)
478: Relationship between Obesity and Prostate Cancer Screening in the United States (2006) (0)
Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data. (2020) (0)
641: Development of Prostate Tissue and/or Prostate Cancer Specific Gene Panel for Defining Circulating Prostate Epithelial Cells (CPECS) (2004) (0)
THE IMPACT OF SOCIOECONOMIC STATUS ON CLINICAL PARAMETERS OF RADICAL PROSTATECTOMY PATIENTS IN AN EQUAL ACCESS HEALTH CARE SYSTEM (1999) (0)
Commentary (Moul)—Testicular Cancer: What’s New in Staging, Prognosis, and Therapy (1999) (0)
Preoperative Staging of Prostate Cancer: The Role of Molecular Markers (2003) (0)
Prostate Cancer SEER Incidence of Distant Disease (1997) (0)
Perineural versus lymphovascular invasion: Which is a better marker for unfavorable biochemical outcomes following prostatectomy? Results from the Duke Prostate Center Database. (2012) (0)
Perspective on Expanding Androgen-Targeted Treatments for Men With Castration-Resistant Prostate Cancer (2014) (0)
Application of active surveillance threshold to series of samples submitted for commercial testing. (2016) (0)
Overview Prostate cancer is the most commonly diagnosed The NCCN Prostate Cancer Early Detection Clinical Practice Guidelines in OncologyTM (2010) (0)
Post-prostatectomy PSA slope (ProsVue) in Gleason score ≥7 disease (2012) (0)
Editorial comment. (2010) (0)
Editorial Comment. (2016) (0)
PHASE I TRIAL OF PROSTATECTOMY AFTER PLANNED PRE-OPERATIVE RADIOTHERAPY FOR HIGH RISK LOCALIZED PROSTATE CANCER: PRELIMINARY RESULTS (2009) (0)
Patient CareEditorial Commentary (2016) (0)
931: Retroperitoneal Lymphadenectomy in Primary Mature Teratoma of the Testis: Is it Indicated? (2004) (0)
Awareness, concern, and communication between physicians and patients on bone health in nonmetastatic prostate cancer. (2012) (0)
Commentary (Moul)—Testicular Cancer: Maintaining the High Cure Rate (2003) (0)
TITLE: Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction RUNNING TITLE: Cerebrospinal Fluid Proteome Changes after Surgery AUTHORS: (2021) (0)
Putting Provenge in perspective. (2011) (0)
A long-term study of the efficacy of treatment of localized prostate cancer. (1997) (0)
Defining an Optimum PSA-Based Screening Strategy for Young Men (2004) (0)
Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression. (2017) (0)
Cancer Protein-coupled Receptor , Is Overexpressed in Prostate , a Novel Prostate-specific Gene with Homology to a G PSGR Updated (2000) (0)
Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy. (2017) (0)
Abstracts from the First International Workshop on Focal Therapy and Imaging of Prostate Cancer, February 21-22, 2008, the Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, North Carolina (2008) (0)
Limitations of tissue microarrays in the evaluation of bcl-2 and P53 expression in whole mount derived prostate tissues (2003) (0)
CYTOLOGIC DETECTION OF CIRCULATING TUMOR CELLS IN LOW VOLUME PROSTATE CANCER (2009) (0)
Editorial comment. (2016) (0)
226: Gene Expression / Biochemical Pathway Signatures of Prostate Cancer Cells of Patients with High Risk and Moderate Risk Progression of Disease (2005) (0)
PERINEAL RADICAL PROSTATECTOMY: WHAT ARE THE TEN YEAR OUTCOMES? (2009) (0)
PREDICTING RECURRENCE IN EARLY DETECTED PROSTATE CANCER USING P53 (1999) (0)
PROSTATE-SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY AND THE RISK OF DEATH (2009) (0)
455: Racial Disparities Remain in Prostate Cancer - An Analysis on 10530 Men Diagnosed During PSA Era (2007) (0)
Molecular Genetics and Markers of Progression (2000) (0)
1490: Correlation of one Core Positive Biopsy for Cancer with Index or Total Tumor Volume Less than 0.5CC in Prostatectomy Specimens (2005) (0)
815: Does Obesity Increase Intraoperative and Postoperative Complications in Men Undergoing Radical Prostatectomy? (2004) (0)
A discussion of general prostate cancer screening versus targeted diagnosis in younger men (2005) (0)
242 EXTERNAL VALIDATION OF THE SEARCH MODEL FOR PREDICTING AGGRESSIVE RECURRENCE AFTER PROSTATECTOMY: RESULTS FROM THE DUKE PROSTATE CENTER DATABASE (2010) (0)
472: Prostate Cancer in Men Less than or Equal to 40 Years of Age During The PSA Era (2004) (0)
New data, new paradigms for treating patients with prostate cancer. Conclusion. (2011) (0)
TICE chemotherapy achieves good response in germ cell tumors. Comment (2005) (0)
WHO DOES NOT NEED FOLLOW UP TWO YEARS AFTER PROSTATECTOMY? AN ANALYSIS OF 1739 PATIENTS AT DUKE UNIVERSITY MEDICAL CENTER (2009) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Judd W. Moul?

Judd W. Moul is affiliated with the following schools:

Judd W. Moul's Academic­Influence.com Rankings

Why Is Judd W. Moul Influential?

Judd W. Moul's Published Works

Published Works

What Schools Are Affiliated With Judd W. Moul?

Judd W. Moul's AcademicInfluence.com Rankings